Bisphosphonates induce breast cancer cell death in vitro.
about
Direct effects of bisphosphonates on breast cancer cells.Should all adjuvant breast cancer patients receive a bisphosphonate?The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxelThe effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice.New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases.Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk.Direct antitumour activity of zoledronic acid: preclinical and clinical data.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.Tumour macrophages as potential targets of bisphosphonates.Bisphosphonate therapy in the oncology setting.Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies.Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interactionIbandronate: efficacy in the treatment of metastatic bone disease.The role of the bone microenvironment in skeletal metastasis.Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer modelZoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κBIntravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibodyAdjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells.Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway.Anticancer properties of zoledronic acid.Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence.Zoledronic acid: multiplicity of use across the cancer continuum.New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.
P2860
Q24802079-C929B7C2-BCF8-4AA0-8775-5D74C6EA5CBFQ24802817-648D7532-6B60-44AA-9FD8-885A29EEAD29Q28362972-9DCB5BDE-B9DC-4DDF-96F7-9E4E94CBFDE4Q33235424-47515198-F685-4C98-BF3A-E8E9DD4CCBAAQ33269187-BFD9DF13-8CD5-4E7A-BB68-8A540D963394Q33326045-66DC72DA-2783-4004-A005-2714C59060D6Q33415020-3E8E4E77-AF7A-410C-B6EF-609E0DE40726Q33708123-A871BBFE-C445-4A9D-A5A6-286E9C67F600Q33850938-68A996DA-F6CA-4EEC-8F7B-8735891607AFQ34145863-7B752C76-EFBF-46EB-ADE6-73B646D52E07Q34348233-1970F874-6FE7-45DA-8FCD-1B884ADBE593Q34480630-CF5F0600-3248-4D25-A5A8-2E1CE0C6235DQ35095225-9F9F1184-03A0-4E66-BCE3-504F7A0B7F04Q35259094-6979EBD3-B2CF-4EE6-BC02-8F67FB701751Q35431110-87720845-B5E0-48A2-B740-63E6AED9CDD2Q35547309-7C4C68BB-0879-4830-A778-76111D57DECFQ35602668-EABEE39C-4F3C-4501-9F2C-EEBD900C6A79Q36034236-25443474-696C-4E2E-A49F-AEE7A771981AQ36097627-21963750-0A67-42BD-96B1-7BE73EDD5C19Q36240183-FDF8CCEC-49FD-4996-9869-282D042FE7F9Q36295928-7F44015C-9766-4C3B-AB41-2317FD7E03D0Q36429562-3B0D345C-6D3A-4392-A73D-F82945C789A8Q36491430-0D9A2F6F-61DA-47E8-A7F4-EC4D3CE2757CQ36643023-8CDC92CD-4049-4DD8-9823-AD3375AAC4DEQ36644394-FDA088FC-0AC5-4D65-8DF2-F73B1511CBEEQ36648924-22A1F7E0-E53A-45CD-9D5B-1A1FB1098ED1Q36670757-84C4EE77-185D-4F00-A341-382CE0644E43Q36695888-70AEC1D1-F024-46CD-AFDB-C5FA6D0FB9BCQ36847530-50F370DC-788B-4D3A-881A-5E0DA258C854Q37012308-159A7C93-816D-4391-BE11-851EA2BC81DDQ37089016-3C084C07-1FE5-4708-8A24-434D0BF14B2AQ37278425-759EC147-12BA-4E9C-9361-DCB6096D7047Q37321938-E05A139B-E6ED-4D61-A41F-13BFA6524886Q37441608-DFAA59B0-D9B8-413E-8412-FDE0E965CF38Q37699431-E0496768-AF23-424C-9025-FE0DE7A34259Q37728428-45C2D9EF-84C1-42F1-A344-4CB7CCF2441CQ37794160-7EC8F195-C6C9-48CA-B72E-E946D8EA6C31Q37845836-8A9F100C-7106-44B5-AE49-69D6747B1AD1Q37909355-60CB2B75-7E36-4214-82B1-B542638B9E83Q37917774-21FF4783-5574-46EB-814E-EDEC346CC15B
P2860
Bisphosphonates induce breast cancer cell death in vitro.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Bisphosphonates induce breast cancer cell death in vitro.
@en
type
label
Bisphosphonates induce breast cancer cell death in vitro.
@en
prefLabel
Bisphosphonates induce breast cancer cell death in vitro.
@en
P2093
P1476
Bisphosphonates induce breast cancer cell death in vitro.
@en
P2093
P304
P356
10.1359/JBMR.2000.15.11.2211
P577
2000-11-01T00:00:00Z